Dr Silvia Gaia and colleagues from Italy evaluated patients with end stage liver cirrhosis following granulocyte-colony stimulating factor administration.
The research team assessed the feasibility, safety and pattern of bone marrow-derived cells mobilization in 8 patients with severe liver cirrhosis.
The patients were treated with granulocyte-colony stimulating factor at 5µg/kg for 3 consecutive days to mobilize bone marrow-derived cells.
Bone marrow-derived cells were evaluated as circulating CD34 positive cells and myeloid progenitors.
Co-expression in CD34 positive cells markers of differentiation were investigated on CD34 positive cells by double direct immunofluorescence.
| Granulocyte-colony stimulating factor was well tolerated|
|Journal of Hepatology|
The team used data from 40 healthy hematopoietic stem cell donors as controls.
The researchers found that mobilization of CD34 positive cells occurred in all patients.
The team noted that this was paralleled by expansion of circulating progenitors.
Circulating CD34 positive cells co-expressed epithelial and stem cell markers in both cirrhotics and volunteer stem cell donors.
In addition, the researchers found that granulocyte-colony stimulating factor was well tolerated.
No adverse event occurred, and the team observed a significant reversible increase of splenic longitudinal diameter.
Dr Gaia's team commented, “Granulocyte-colony stimulating factor mobilization of bone marrow-derived cells co-expressing epithelial and stem markers occurred in all cirrhotic patients.”
“Splenomegaly up to 170mm does not prevent safe bone marrow-derived cells mobilization following granulocyte-colony stimulating factor in patients with end stage liver disease.”
“Mobilized bone marrow-derived cells may represent an easy immature cell source potentially useful for novel approaches for liver regeneration.”